C2i Genomics: Mark Oldroyd, Ravi Kandasamy, Alex Parker
C2i Genomics has appointed Mark Oldroyd as its chief business officer, Ravi Kandasamy as VP of research and development, and Alex Parker as a member of the firm's board of directors.
Oldroyd previously served as senior VP at Tempus. Prior to Tempus, he was a senior director at Foundation Medicine.
Kandasamy most recently served as director of genomics at Bristol-Myers Squibb. In addition, he has previously served as manager of research and development in precision medicine at GlaxoSmithKline.
Parker currently serves as senior VP for clinical product strategy at Thrive Earlier Detection. Prior to Thrive, he spent more than seven years in leadership positions at Foundation Medicine.